Elfi Birsa

Elfi Birsa

Auto-generated profile, based on publicly available information

Elfi Birsa

COBIK, Ajdovscina, Slovenia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2022 in Microbial Biotechnology
Verified
Journal Article
Open access
ALAna Lisac
Ana Lisac
EBElfi Birsa
Elfi Birsa
APAleš Podgornik
Aleš Podgornik
Summary: A system consisting of a connected mixed and tubular bioreactor was designed to study bacterial biofilm formation and the effect of its exposure to bacteriophages under different experimental conditions. The bacterial biofilm inside silicone tubular bioreactor was formed during the continuous pumping of bacterial cells at a constant physiological state for 2 h and subsequent washing with a buffer for 24 h. Monitoring bacterial and bacteriophage concentration along the tubular bioreactor was performed via a piercing method. The presence of biofilm and planktonic cells was demonstrated by combining the piercing method, measurement of planktonic cell concentration at the tubular bioreactor outlet, and optical microscopy. The planktonic cell formation rate was found to be 8.95 × 10 −3 h −1 and increased approximately four‐fold (4×) after biofilm exposure to an LB medium. Exposure of bacterial biofilm to bacteriophages in the LB medium resulted in a rapid decrease of biofilm and planktonic cell concentration, to below the detection limit within < 2 h. When bacteriophages were supplied in the buffer, only a moderate decrease in the concentration of both bacterial cell types was observed. After biofilm washing with buffer to remove unadsorbed bacteriophages, its exposure to the LB medium (without bacteriophages) resulted in a rapid decrease in bacterial concentration: again below the detection limit in < 2 h.

31 December 2025 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
UBUrban Bezeljak
Urban Bezeljak
AJAlexander Jerman
Alexander Jerman
TKTina Kobal
Tina Kobal
MKMartina Lokar Kosmač
Martina Lokar Kosmač
EBElfi Birsa
Elfi Birsa
MPMatjaž Peterka
Matjaž Peterka
Nipah virus (NiV) is an emerging high-fatality zoonotic threat lacking approved vaccines. Current virus-like particle (VLP) production methods rely on cost

24 August 2025 in bioRxiv
Verified
Preprint
Open access
UBUrban Bezeljak
Urban Bezeljak
AJAlexander Jerman
Alexander Jerman
TKTina Kobal
Tina Kobal
MKMartina Lokar Kosmač
Martina Lokar Kosmač
EBElfi Birsa
Elfi Birsa
MPMatjaž Peterka
Matjaž Peterka
Nipah virus (NiV) is an emerging high-fatality zoonotic threat lacking approved vaccines. Current virus-like particle (VLP) production methods rely on costly mammalian cell systems and non-scalable ultracentrifugation purification. We developed an efficient production system for enveloped NiVLPs by co-expressing structural proteins F, G, and M using a baculovirus expression vector system in Sf9 cells. A novel multi-step chromatographic purification process was established using monolith convective media, integrating steric exclusion chromatography with sequential cation and anion exchange steps. Purified NiVLPs were characterized by nanoparticle tracking analysis and transmission electron microscopy, then evaluated for immunogenicity in Syrian golden hamsters. The optimized process yielded enveloped particles of approximately 100-120 nm that morphologically resemble native NiV virions. A single 25 μg NiVLP dose induced robust systemic anti-NiV G IgG responses within 14 days, demonstrating rapid immunogenicity suitable for outbreak response. However, neutralizing antibody titers against NiV remained limited compared to total IgG responses. This study establishes the first chromatography-based manufacturing platform for morphologically correct NiVLPs from insect cells. A deeper understanding of the immunity generated is needed to support their potential as a rapidly deployable vaccine platform against NiV.